Form 4: Surgery Partners Director Plans Future Stock Sale

Surgery Partners Director Teresa DeLuca reported a pre-planned sale of 20,018 shares of common stock for $22.74 per share, effective August 11, 2025.

Summary

• Director Teresa DeLuca reported a planned sale of 20,018 shares of Surgery Partners, Inc. common stock.
• The sale is scheduled to occur on August 11, 2025, at a weighted average price of $22.74 per share, executed under a Rule 10b5-1 trading plan.
• Following this planned transaction, Ms. DeLuca is expected to directly own 45,173 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports a pre-planned sale by a director under a Rule 10b5-1 plan, which is a routine financial management activity and does not necessarily indicate a negative outlook on the company's future performance. It's a neutral event.

Negatives

• A director has a pre-planned sale of 20,018 shares of common stock, which will reduce their direct ownership.

Risks

• The planned sale by a director, even under a 10b5-1 plan, could be perceived by some investors as a lack of strong future confidence, potentially impacting investor sentiment.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Director Teresa DeLuca reported a planned sale of 20,018 shares of common stock to occur on August 11, 2025, at $22.74 per share, executed under a Rule 10b5-1 trading plan.

Stakeholder Impact

• Shareholders: The planned sale by a director, even under a 10b5-1 plan, might lead to questions about future stock performance, though it's often for personal financial planning and diversification.

Key Dates

Recommendation

The filing reports a future planned sale of common stock by a director under a Rule 10b5-1 trading plan. Such plans are pre-arranged and do not necessarily reflect a change in the director's immediate outlook on the company. While a sale reduces insider ownership, this specific transaction, being pre-planned and for a future date, does not provide a strong immediate signal for a buy or sell recommendation. Investors should consider it as part of routine insider financial management.

Keywords

Surgery Partners, SGRY, insider trading, stock sale, director, common stock, SEC Form 4, 10b5-1 plan